In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

After a half-century wait, a new drug has been approved for the treatment of systemic lupus erythematosus. The success of belimumab could bolster the feasibility of B-cell-targeted approaches to ...

Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...

Researchers assessed factors influencing contraceptive counseling and use among women with rheumatic disease, including ethnicity, language, and age.

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...

Coming Therapies for Cutaneous Lupus Relevant for Derms Dermatologists long reluctant to tackle cutaneous lupus erythematosus may be more open to treating patients with approvals that promise to ...

Critically ill patients with systemic lupus erythematosus show reduced ICU survival, driven largely by renal dysfunction, with glucocorticoids potentially mitigating mortality risk.

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Telitacicept in combination with standard therapy was effective for the treatment of systemic lupus erythematosus through 52 weeks.

Worldwide incidence and prevalence estimates of systemic lupus erythematosus (SLE) vary substantially and are influenced by ethnic and geographic differences, study design and environmental exposures ...

What is Systemic Lupus Erythematosus? Systemic Lupus Erythematosus (SLE) is a chronic disease with many manifestations. It is an autoimmune disease in which the body's immune system is directed ...